Literature DB >> 34035764

A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis.

David T Rubin1, Cindy Traboulsi1, Victoria Rai1.   

Abstract

Patients with ulcerative colitis (UC) can experience periods of recurrent disease activity with a range of symptoms, including abdominal pain, rectal bleeding, urgency, and diarrhea. Although long-term remission will be achieved and maintained in most cases, the course of UC varies from patient to patient. Patients can be defined according to whether they are in remission or have mild, moderate, severe, or fulminant disease, and hospitalization can occur under different circumstances. In these cases, determining the next course of therapy is essential. The aim of this article is to present an approach to the treatment of high-risk UC in both the outpatient and inpatient settings. Also presented is a critical appraisal of alternative and emerging approaches to the management of patients with high-risk UC. Fundamental principles are key in the management of high-risk UC, including discussing the goals of treatment with the patient and family, assessing each patient's risk level and prognostic factors in addition to disease activity to inform therapeutic choices, understanding drug mechanisms and pharmacokinetics, and using objective measures to monitor disease response. In the treatment of all patients with high-risk UC, a balanced approach to deciding between medical and surgical options must be maintained.
Copyright © 2021, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Ulcerative colitis; colectomy; cyclosporine; infliximab; management

Year:  2021        PMID: 34035764      PMCID: PMC8132723     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  50 in total

1.  The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women.

Authors:  N Pedersen; A Bortoli; D Duricova; R D Inca; M R Panelli; J P Gisbert; G Zoli; A López-Sanromán; F Castiglione; G Riegler; V Annese; P Gionchetti; A Prada; E D Pont; A Timmer; C Felley; M Shuhaibar; E V Tsianos; C Dejaco; F J Baert; T Jess; M Lebech; D W Hommes; P Munkholm
Journal:  Aliment Pharmacol Ther       Date:  2013-07-15       Impact factor: 8.171

2.  Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.

Authors:  Gauthier Pellet; Carmen Stefanescu; Franck Carbonnel; Laurent Peyrin-Biroulet; Xavier Roblin; Christophe Allimant; Maria Nachury; Stephane Nancey; Jerome Filippi; Romain Altwegg; Hedia Brixi; Ginette Fotsing; Laure de Rosamel; Sarah Shili; David Laharie
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

Review 3.  Ulcerative Colitis Care Pathway.

Authors:  Themistocles Dassopoulos; Russell D Cohen; Ellen J Scherl; Ronald M Schwartz; Lawrence Kosinski; Miguel D Regueiro
Journal:  Gastroenterology       Date:  2015-05-27       Impact factor: 22.682

4.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Authors:  Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

Review 5.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

6.  Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.

Authors:  Meenakshi Bewtra; Craig W Newcomb; Qufei Wu; Lang Chen; Fenglong Xie; Jason A Roy; Cary B Aarons; Mark T Osterman; Kimberly A Forde; Jeffrey R Curtis; James D Lewis
Journal:  Ann Intern Med       Date:  2015-08-18       Impact factor: 25.391

7.  Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients.

Authors:  Greta Ra; Reka Thanabalan; Sahana Ratneswaran; Geoffrey C Nguyen
Journal:  J Crohns Colitis       Date:  2013-03-26       Impact factor: 9.071

8.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

9.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Authors:  Omoniyi J Adedokun; William J Sandborn; Brian G Feagan; Paul Rutgeerts; Zhenhua Xu; Colleen W Marano; Jewel Johanns; Honghui Zhou; Hugh M Davis; Freddy Cornillie; Walter Reinisch
Journal:  Gastroenterology       Date:  2014-08-28       Impact factor: 22.682

10.  Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications.

Authors:  J Randall; B Singh; B F Warren; S P L Travis; N J Mortensen; B D George
Journal:  Br J Surg       Date:  2010-03       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.